Assessing End-To-End Drug Development Partnerships
As drug development becomes increasingly expensive and complex, pharma companies are relying on the services of contract development and manufacturing organizations (CDMOs) to aid them in the creation and commercialization of their products. Exemplifying this, 80% of manufacturing by small biotech and pharma companies was outsourced in 2017.
This practice allows companies to reserve precious resources for business growth activities, while CDMO partners with extensive experience and expertise can focus on the development and production of their pipelines.
Read our whitepaper to learn more about how pharma and biotech companies make decisions on CDMO selection, and what benefits there are to end-to-end partnerships.